Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Best of the 2007 AUA Annual Meeting</title><author><name sortKey="Brawer, Michael K" sort="Brawer, Michael K" uniqKey="Brawer M" first="Michael K" last="Brawer">Michael K. Brawer</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">17934570</idno><idno type="pmc">2002503</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2002503</idno><idno type="RBID">PMC:2002503</idno><date when="2007">2007</date><idno type="wicri:Area/Pmc/Corpus">000202</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000202</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Best of the 2007 AUA Annual Meeting</title><author><name sortKey="Brawer, Michael K" sort="Brawer, Michael K" uniqKey="Brawer M" first="Michael K" last="Brawer">Michael K. Brawer</name></author></analytic><series><title level="j">Reviews in Urology</title><idno type="ISSN">1523-6161</idno><imprint><date when="2007">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader></TEI><pmc article-type="meeting-report"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Rev Urol</journal-id><journal-id journal-id-type="publisher-id">RIU</journal-id><journal-title>Reviews in Urology</journal-title><issn pub-type="ppub">1523-6161</issn><publisher><publisher-name>MedReviews, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17934570</article-id><article-id pub-id-type="pmc">2002503</article-id><article-id pub-id-type="other">1523-6161-9-3-133</article-id><article-categories><subj-group subj-group-type="heading"><subject>Meeting Review</subject></subj-group></article-categories><title-group><article-title>Best of the 2007 AUA Annual Meeting</article-title><subtitle>Highlights from the 2007 Annual Meeting of the American Urological Association, May 19–24, 2007, Anaheim, CA</subtitle></title-group><contrib-group><contrib contrib-type="author"><name><surname>Brawer</surname><given-names>Michael K</given-names></name><degrees>MD</degrees></contrib><aff><institution>Threshold Pharmaceuticals</institution></aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Makarov</surname><given-names>Danil V</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author"><name><surname>Partin</surname><given-names>Alan W</given-names></name><degrees>MD, PhD</degrees></contrib><aff><institution>The Johns Hopkins Medical Institutions and Hospital</institution></aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Roehrborn</surname><given-names>Claus G</given-names></name><degrees>MD</degrees></contrib><aff><institution>University of Texas Southwestern Medical Center</institution></aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Curtis Nickel</surname><given-names>J</given-names></name><degrees>MD, FRCSC</degrees></contrib><aff><institution>Queen’s University</institution></aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Chancellor</surname><given-names>Michael B</given-names></name><degrees>MD</degrees></contrib><aff><institution>University of Pittsburgh School of Medicine</institution></aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Assimos</surname><given-names>Dean G</given-names></name><degrees>MD</degrees></contrib><aff><institution>Wake Forest University School of Medicine</institution></aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Shapiro</surname><given-names>Ellen</given-names></name><degrees>MD, FACS, FAAP</degrees></contrib><aff><institution>New York University School of Medicine</institution></aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Rajfer</surname><given-names>Jacob</given-names></name><degrees>MD</degrees></contrib><aff><institution>University of California at Los Angeles</institution></aff></contrib-group><pub-date pub-type="ppub"><season>Summer</season><year>2007</year></pub-date><volume>9</volume><issue>3</issue><fpage>133</fpage><lpage>154</lpage><permissions><copyright-statement>© 2007 MedReviews, LLC</copyright-statement><copyright-year>2007</copyright-year><copyright-holder>MedReviews, LLC</copyright-holder></permissions><kwd-group><title>Key words</title><kwd>Prostate cancer</kwd><kwd>Prostate-specific antigen</kwd><kwd>Obesity</kwd><kwd>PSA velocity</kwd><kwd>Repeat biopsy</kwd><kwd>Human glandular kallikrein</kwd><kwd>Expectant management</kwd><kwd>Biomarkers</kwd><kwd>PCA3</kwd><kwd>EPCA-2</kwd><kwd>CRISP-3</kwd><kwd>MSP</kwd><kwd>Testosterone</kwd><kwd>Microvessel density</kwd><kwd>Endoglin</kwd><kwd>Survivin</kwd><kwd>Telomeres</kwd><kwd>Male voiding dysfunction</kwd><kwd>Lower urinary tract symptoms</kwd><kwd>Interleukin-8</kwd><kwd>Botulinum toxin</kwd><kwd>PDE-5 inhibitors</kwd><kwd>Antimuscarinic agents</kwd><kwd>Benign prostatic hyperplasia</kwd><kwd>Acute urinary retention</kwd><kwd>5Alpha-reductase inhibitors</kwd><kwd>Nocturia</kwd><kwd>Doxazosin</kwd><kwd>Finasteride</kwd><kwd>LHRH antagonists</kwd><kwd>Laser ablation</kwd><kwd>Transurethral microwave thermotherapy</kwd><kwd>TURP</kwd><kwd>Perioperative blood loss</kwd><kwd>Urinary tract infections</kwd><kwd>Microbial biofilms</kwd><kwd>Circumcision</kwd><kwd>HIV</kwd><kwd>Antibiotic prophylaxis</kwd><kwd>Stress urinary incontinence</kwd><kwd>Stem cell injection</kwd><kwd>Endourology</kwd><kwd>Urolithiasis</kwd><kwd>Ureteral stents</kwd><kwd>Medical expulsive therapy</kwd><kwd>Shock wave lithotripsy</kwd><kwd>Hyperoxaluria</kwd><kwd>Pregnancy</kwd><kwd>Erectile dysfunction</kwd><kwd>Prostatectomy</kwd><kwd>Peyronie’s disease</kwd><kwd>Ejaculatory dysfunction</kwd><kwd>Vesicoureteral reflux</kwd><kwd>Laparoscopic orchiopexy</kwd><kwd>Bladder exstrophy</kwd><kwd>Sexual function</kwd><kwd>Infertility</kwd></kwd-group></article-meta></front><floats-wrap><fig id="F1" position="float"><label>Figure 1</label><caption><p><italic>Predicted decrease in IPSS during placebo run-in. IPSS, International Prostate Symptom Score. Reprinted from Roehrborn et al<xref rid="B38" ref-type="bibr">38</xref> with permission from the American Urological Association</italic>.</p></caption><graphic xlink:href="RIU009003_0133_fig001"></graphic></fig><fig id="F2" position="float"><label>Figure 2</label><caption><p><italic>Dose-dependent improvement in IPSS with ozarelix. IPSS, International Prostate Symptom Score. Data from Debruyne<xref rid="B46" ref-type="bibr">46</xref></italic>.</p></caption><graphic xlink:href="RIU009003_0133_fig002"></graphic></fig><fig id="F3" position="float"><label>Figure 3</label><caption><p><italic>Relationship between symptomatic improvement and prostate volume change with botulinum toxin treatment. IPSS, International Prostate Symptom Score; Qmax, maximum flow rate; QOL, quality of life. Reprinted from Chuang et al<xref rid="B51" ref-type="bibr">51</xref> with permission from the American Urological Association</italic>.</p></caption><graphic xlink:href="RIU009003_0133_fig003"></graphic></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Association Between Waist Circumference and Parameters Associated With Voiding and Sexual Health</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"></th><th colspan="3" rowspan="1">Waist Circumference (inches)<hr></hr></th><th rowspan="1" colspan="1"></th></tr><tr><th rowspan="1" colspan="1"></th><th rowspan="1" colspan="1">30–36 (n = 27)</th><th rowspan="1" colspan="1">36–40 (n = 36)</th><th rowspan="1" colspan="1">> 40 (n = 25)</th><th rowspan="1" colspan="1"><italic>P</italic> Value</th></tr></thead><tbody valign="top"><tr><td rowspan="1" colspan="1">Age, years</td><td rowspan="1" colspan="1">61.39</td><td rowspan="1" colspan="1">62.36</td><td rowspan="1" colspan="1">63.89</td><td rowspan="1" colspan="1"><.08</td></tr><tr><td rowspan="1" colspan="1">PV, cc</td><td rowspan="1" colspan="1">28.53</td><td rowspan="1" colspan="1">31.67</td><td rowspan="1" colspan="1">36.78</td><td rowspan="1" colspan="1"><.001</td></tr><tr><td rowspan="1" colspan="1">PSA, ng/mL</td><td rowspan="1" colspan="1">2.32</td><td rowspan="1" colspan="1">2.92</td><td rowspan="1" colspan="1">3.54</td><td rowspan="1" colspan="1"><.003</td></tr><tr><td rowspan="1" colspan="1">IPSS at Screening</td><td rowspan="1" colspan="1">11.57</td><td rowspan="1" colspan="1">13.67</td><td rowspan="1" colspan="1">15.78</td><td rowspan="1" colspan="1"><.001</td></tr><tr><td rowspan="1" colspan="1">Diabetic, %</td><td rowspan="1" colspan="1">11.2</td><td rowspan="1" colspan="1">22.3</td><td rowspan="1" colspan="1">34.5</td><td rowspan="1" colspan="1">.001</td></tr><tr><td rowspan="1" colspan="1">Hypertension, %</td><td rowspan="1" colspan="1">12.6</td><td rowspan="1" colspan="1">24.7</td><td rowspan="1" colspan="1">37.8</td><td rowspan="1" colspan="1">.001</td></tr><tr><td rowspan="1" colspan="1">Qmax, mL/sec</td><td rowspan="1" colspan="1">10.6</td><td rowspan="1" colspan="1">9.45</td><td rowspan="1" colspan="1">8.65</td><td rowspan="1" colspan="1">.03</td></tr><tr><td rowspan="1" colspan="1">ED, %</td><td rowspan="1" colspan="1">34.6</td><td rowspan="1" colspan="1">49.5</td><td rowspan="1" colspan="1">78.6</td><td rowspan="1" colspan="1">.002</td></tr><tr><td rowspan="1" colspan="1">EjD, %</td><td rowspan="1" colspan="1">27.8</td><td rowspan="1" colspan="1">47.2</td><td rowspan="1" colspan="1">74.5</td><td rowspan="1" colspan="1">.002</td></tr></tbody></table><table-wrap-foot><fn><p>PV, prostate volume; PSA, prostate-specific antigen; IPSS, International Prostate Symptom Score; Qmax, maximum flow rate; ED, erectile dysfunction; EjD, ejaculatory dysfunction. Reprinted from Kaplan et al<xref rid="B32" ref-type="bibr">32</xref> with permission from the American Urological Association.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Age Specific Mortality Rates and Standardized Mortality Ratios (SMR) After AUR</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"></th><th colspan="3" rowspan="1">Mortality Rate % (95% CI)<hr></hr></th><th rowspan="1" colspan="1">SMR (95% CI)<hr></hr></th></tr><tr><th rowspan="1" colspan="1">Age Group</th><th rowspan="1" colspan="1">30 Days</th><th rowspan="1" colspan="1">90 Days</th><th rowspan="1" colspan="1">365 Days</th><th rowspan="1" colspan="1">365 Days</th></tr></thead><tbody valign="top"><tr><td rowspan="1" colspan="1">45–54</td><td rowspan="1" colspan="1">1.05 (0.82–1.34)</td><td rowspan="1" colspan="1">2.23 (1.88–2.64)</td><td rowspan="1" colspan="1">4.23 (3.74–4.79)</td><td rowspan="1" colspan="1">10.36 (9.14–11.75)</td></tr><tr><td rowspan="1" colspan="1">55–64</td><td rowspan="1" colspan="1">1.06 (0.91–1.24)</td><td rowspan="1" colspan="1">2.36 (2.13–2.61)</td><td rowspan="1" colspan="1">5.61 (5.25–6.00)</td><td rowspan="1" colspan="1">5.28 (4.93–5.65)</td></tr><tr><td rowspan="1" colspan="1">65–74</td><td rowspan="1" colspan="1">1.84 (1.71–1.99)</td><td rowspan="1" colspan="1">4.21 (4.01–4.43)</td><td rowspan="1" colspan="1">10.16 (9.84–10.49)</td><td rowspan="1" colspan="1">3.43 (3.32–3.55)</td></tr><tr><td rowspan="1" colspan="1">75–84</td><td rowspan="1" colspan="1">2.98 (2.82–3.14)</td><td rowspan="1" colspan="1">7.39 (7.15–7.64)</td><td rowspan="1" colspan="1">18.32 (17.95–18.69)</td><td rowspan="1" colspan="1">2.33 (2.28–2.39)</td></tr><tr><td rowspan="1" colspan="1">85–100</td><td rowspan="1" colspan="1">6.01 (5.66–6.38)</td><td rowspan="1" colspan="1">14.47 (13.95–15.01)</td><td rowspan="1" colspan="1">32.10 (31.38–32.83)</td><td rowspan="1" colspan="1">1.64 (1.59–1.68)</td></tr></tbody></table><table-wrap-foot><fn><p>AUR, acute urinary retention. Reprinted from Armitage et al<xref rid="B36" ref-type="bibr">36</xref> with permission from the American Urological Association.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Effect of Placebo vs Doxazosin vs Finasteride vs Combination Therapy on Nocturia Episodes at Year 1 and Year 4</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"></th><th colspan="2" rowspan="1">Placebo<hr></hr></th><th colspan="2" rowspan="1">Doxazosin<hr></hr></th><th colspan="2" rowspan="1">Finasteride<hr></hr></th><th colspan="2" rowspan="1">Combination<hr></hr></th></tr><tr><th rowspan="1" colspan="1"></th><th rowspan="1" colspan="1"></th><th rowspan="1" colspan="1">Mean</th><th rowspan="1" colspan="1"></th><th rowspan="1" colspan="1">Mean</th><th rowspan="1" colspan="1"></th><th rowspan="1" colspan="1">Mean</th><th rowspan="1" colspan="1"></th><th rowspan="1" colspan="1">Mean</th></tr><tr><th rowspan="1" colspan="1"></th><th rowspan="1" colspan="1">#</th><th rowspan="1" colspan="1">Change</th><th rowspan="1" colspan="1">#</th><th rowspan="1" colspan="1">Change</th><th rowspan="1" colspan="1">#</th><th rowspan="1" colspan="1">Change</th><th rowspan="1" colspan="1">#</th><th rowspan="1" colspan="1">Change</th></tr></thead><tbody valign="top"><tr><td colspan="9" rowspan="1">Participants completing at least 1 year of trial with ≥ 1 episode nocturia at baseline</td></tr><tr><td rowspan="1" colspan="1">Year 1</td><td rowspan="1" colspan="1">628</td><td rowspan="1" colspan="1">−0.35</td><td rowspan="1" colspan="1">649</td><td rowspan="1" colspan="1">−0.54<xref ref-type="table-fn" rid="TF1">*</xref><xref ref-type="table-fn" rid="TF2">†</xref></td><td rowspan="1" colspan="1">653</td><td rowspan="1" colspan="1">−0.40</td><td rowspan="1" colspan="1">653</td><td rowspan="1" colspan="1">−0.58<xref ref-type="table-fn" rid="TF1">*</xref><xref ref-type="table-fn" rid="TF2">†</xref></td></tr><tr><td rowspan="1" colspan="1">Year 4</td><td rowspan="1" colspan="1">488</td><td rowspan="1" colspan="1">−0.38</td><td rowspan="1" colspan="1">533</td><td rowspan="1" colspan="1">−0.53<xref ref-type="table-fn" rid="TF1">*</xref></td><td rowspan="1" colspan="1">516</td><td rowspan="1" colspan="1">−0.42</td><td rowspan="1" colspan="1">528</td><td rowspan="1" colspan="1">−0.55<xref ref-type="table-fn" rid="TF1">*</xref></td></tr><tr><td colspan="9" rowspan="1">Subgroup analyses</td></tr><tr><td colspan="9" rowspan="1">Participants < 70 years of age<xref ref-type="table-fn" rid="TF3">‡</xref></td></tr><tr><td rowspan="1" colspan="1">Year 1</td><td rowspan="1" colspan="1">501</td><td rowspan="1" colspan="1">−0.41</td><td rowspan="1" colspan="1">521</td><td rowspan="1" colspan="1">−0.56<xref ref-type="table-fn" rid="TF1">*</xref><xref ref-type="table-fn" rid="TF2">†</xref></td><td rowspan="1" colspan="1">527</td><td rowspan="1" colspan="1">−0.43</td><td rowspan="1" colspan="1">539</td><td rowspan="1" colspan="1">−0.61<xref ref-type="table-fn" rid="TF1">*</xref><xref ref-type="table-fn" rid="TF2">†</xref></td></tr><tr><td rowspan="1" colspan="1">Year 4</td><td rowspan="1" colspan="1">389</td><td rowspan="1" colspan="1">−0.46</td><td rowspan="1" colspan="1">428</td><td rowspan="1" colspan="1">−0.52</td><td rowspan="1" colspan="1">417</td><td rowspan="1" colspan="1">−0.45</td><td rowspan="1" colspan="1">442</td><td rowspan="1" colspan="1">−0.58<xref ref-type="table-fn" rid="TF2">†</xref></td></tr><tr><td colspan="9" rowspan="1">Participants ≥ 70 years of age</td></tr><tr><td rowspan="1" colspan="1">Year 1</td><td rowspan="1" colspan="1">127</td><td rowspan="1" colspan="1">−0.11</td><td rowspan="1" colspan="1">128</td><td rowspan="1" colspan="1">−0.46<xref ref-type="table-fn" rid="TF1">*</xref></td><td rowspan="1" colspan="1">126</td><td rowspan="1" colspan="1">−0.29<xref ref-type="table-fn" rid="TF1">*</xref></td><td rowspan="1" colspan="1">114</td><td rowspan="1" colspan="1">−0.42<xref ref-type="table-fn" rid="TF1">*</xref></td></tr><tr><td rowspan="1" colspan="1">Year 4</td><td rowspan="1" colspan="1">99</td><td rowspan="1" colspan="1">−0.08</td><td rowspan="1" colspan="1">105</td><td rowspan="1" colspan="1">−0.59<xref ref-type="table-fn" rid="TF1">*</xref></td><td rowspan="1" colspan="1">99</td><td rowspan="1" colspan="1">−0.29</td><td rowspan="1" colspan="1">89</td><td rowspan="1" colspan="1">−0.40<xref ref-type="table-fn" rid="TF1">*</xref></td></tr><tr><td colspan="9" rowspan="1">Participants, all ages, with 2 or more nocturia episodes at baseline</td></tr><tr><td rowspan="1" colspan="1">Year 1</td><td rowspan="1" colspan="1">459</td><td rowspan="1" colspan="1">−0.61</td><td rowspan="1" colspan="1">484</td><td rowspan="1" colspan="1">−0.77<xref ref-type="table-fn" rid="TF1">*</xref><xref ref-type="table-fn" rid="TF2">†</xref></td><td rowspan="1" colspan="1">496</td><td rowspan="1" colspan="1">−0.60</td><td rowspan="1" colspan="1">487</td><td rowspan="1" colspan="1">−0.80<xref ref-type="table-fn" rid="TF1">*</xref><xref ref-type="table-fn" rid="TF2">†</xref></td></tr><tr><td rowspan="1" colspan="1">Year 4</td><td rowspan="1" colspan="1">354</td><td rowspan="1" colspan="1">−0.66</td><td rowspan="1" colspan="1">393</td><td rowspan="1" colspan="1">−0.77</td><td rowspan="1" colspan="1">385</td><td rowspan="1" colspan="1">−0.68</td><td rowspan="1" colspan="1">393</td><td rowspan="1" colspan="1">−0.79</td></tr></tbody></table><table-wrap-foot><fn id="TF1"><label>*</label><p><italic>P</italic> < .05 versus placebo.</p></fn><fn id="TF2"><label>†</label><p><italic>P</italic> < .05 versus finasteride.</p></fn><fn id="TF3"><label>‡</label><p>There is a treatment versus time interaction for men < 70 who were allocated to doxazosin when compared with those allocated to finasteride.</p></fn><fn><p>Data from Johnson et al.<xref rid="B41" ref-type="bibr">41</xref></p></fn></table-wrap-foot></table-wrap><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Long-Term Outcome of Laser Ablation vs Transurethral Resection of Prostate</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"></th><th colspan="3" rowspan="1">ILC (n = 100)<hr></hr></th><th colspan="3" rowspan="1">TURP (n = 50)<hr></hr></th></tr><tr><th rowspan="1" colspan="1"></th><th rowspan="1" colspan="1">IPSS</th><th rowspan="1" colspan="1">QOL</th><th rowspan="1" colspan="1">Qmax</th><th rowspan="1" colspan="1">IPSS</th><th rowspan="1" colspan="1">QOL</th><th rowspan="1" colspan="1">Qmax</th></tr></thead><tbody valign="top"><tr><td rowspan="1" colspan="1">Pre-op</td><td rowspan="1" colspan="1">20.5 ± 5<xref ref-type="table-fn" rid="TF4">*</xref></td><td rowspan="1" colspan="1">4.2 ± 1<xref ref-type="table-fn" rid="TF4">*</xref></td><td rowspan="1" colspan="1">8.4 ± 2<xref ref-type="table-fn" rid="TF4">*</xref></td><td rowspan="1" colspan="1">20.1 ± 5<xref ref-type="table-fn" rid="TF4">*</xref></td><td rowspan="1" colspan="1">3.8 ± 1<xref ref-type="table-fn" rid="TF4">*</xref></td><td rowspan="1" colspan="1">8.4 ± 2<xref ref-type="table-fn" rid="TF4">*</xref></td></tr><tr><td rowspan="1" colspan="1">1 year</td><td rowspan="1" colspan="1">6.7 ± 6<xref ref-type="table-fn" rid="TF4">*</xref></td><td rowspan="1" colspan="1">1.6 ± 1<xref ref-type="table-fn" rid="TF4">*</xref></td><td rowspan="1" colspan="1">17.2 ± 6<xref ref-type="table-fn" rid="TF4">*</xref></td><td rowspan="1" colspan="1">5.1 ± 4<xref ref-type="table-fn" rid="TF4">*</xref></td><td rowspan="1" colspan="1">1.0 ± 1<xref ref-type="table-fn" rid="TF4">*</xref></td><td rowspan="1" colspan="1">21 ± 11<xref ref-type="table-fn" rid="TF4">*</xref></td></tr><tr><td rowspan="1" colspan="1">2 years</td><td rowspan="1" colspan="1">7.0 ± 6<xref ref-type="table-fn" rid="TF4">*</xref></td><td rowspan="1" colspan="1">1.7 ± 2<xref ref-type="table-fn" rid="TF4">*</xref></td><td rowspan="1" colspan="1">17.3 ± 7<xref ref-type="table-fn" rid="TF4">*</xref></td><td rowspan="1" colspan="1">5.8 ± 5<xref ref-type="table-fn" rid="TF4">*</xref></td><td rowspan="1" colspan="1">1.1 ± 1<xref ref-type="table-fn" rid="TF4">*</xref></td><td rowspan="1" colspan="1">19 ± 10<xref ref-type="table-fn" rid="TF4">*</xref></td></tr><tr><td rowspan="1" colspan="1">3 years</td><td rowspan="1" colspan="1">7.0 ± 5<xref ref-type="table-fn" rid="TF4">*</xref></td><td rowspan="1" colspan="1">1.5 ± 1<xref ref-type="table-fn" rid="TF4">*</xref></td><td rowspan="1" colspan="1">16.2 ± 7<xref ref-type="table-fn" rid="TF4">*</xref></td><td rowspan="1" colspan="1">4.9 ± 4<xref ref-type="table-fn" rid="TF4">*</xref></td><td rowspan="1" colspan="1">1.0 ± 1<xref ref-type="table-fn" rid="TF4">*</xref></td><td rowspan="1" colspan="1">21.7 ± 11<xref ref-type="table-fn" rid="TF4">*</xref></td></tr><tr><td rowspan="1" colspan="1">4 years</td><td rowspan="1" colspan="1">7.3 ± 6<xref ref-type="table-fn" rid="TF4">*</xref></td><td rowspan="1" colspan="1">1.7 ± 1<xref ref-type="table-fn" rid="TF4">*</xref></td><td rowspan="1" colspan="1">17.6 ± 8<xref ref-type="table-fn" rid="TF4">*</xref></td><td rowspan="1" colspan="1">5.6 ± 5<xref ref-type="table-fn" rid="TF4">*</xref></td><td rowspan="1" colspan="1">1.0 ± 1<xref ref-type="table-fn" rid="TF4">*</xref></td><td rowspan="1" colspan="1">18.9 ± 11<xref ref-type="table-fn" rid="TF4">*</xref></td></tr><tr><td rowspan="1" colspan="1">5 years</td><td rowspan="1" colspan="1">6.7 ± 5<xref ref-type="table-fn" rid="TF4">*</xref></td><td rowspan="1" colspan="1">1.5 ± 1<xref ref-type="table-fn" rid="TF4">*</xref></td><td rowspan="1" colspan="1">16.1 ± 6<xref ref-type="table-fn" rid="TF4">*</xref></td><td rowspan="1" colspan="1">5.8 ± 6<xref ref-type="table-fn" rid="TF4">*</xref></td><td rowspan="1" colspan="1">1.0 ± 1<xref ref-type="table-fn" rid="TF4">*</xref></td><td rowspan="1" colspan="1">20.3 ± 11<xref ref-type="table-fn" rid="TF4">*</xref></td></tr><tr><td rowspan="1" colspan="1">6 years</td><td rowspan="1" colspan="1">8.0 ± 6<xref ref-type="table-fn" rid="TF4">*</xref></td><td rowspan="1" colspan="1">1.6 ± 1<xref ref-type="table-fn" rid="TF4">*</xref></td><td rowspan="1" colspan="1">14.6 ± 6<xref ref-type="table-fn" rid="TF4">*</xref></td><td rowspan="1" colspan="1">5.5 ± 4<xref ref-type="table-fn" rid="TF4">*</xref></td><td rowspan="1" colspan="1">1.0 ± 1<xref ref-type="table-fn" rid="TF4">*</xref></td><td rowspan="1" colspan="1">20.8 ± 11<xref ref-type="table-fn" rid="TF4">*</xref></td></tr></tbody></table><table-wrap-foot><fn id="TF4"><label>*</label><p><italic>P</italic> value < .001. ILC, Indigo laser; TURP, transurethral resection of prostate; IPSS, International Prostate Symptom Score; QOL, quality of life; Qmax, maximum flow rate. Reprinted from Chandrasekar et al<xref rid="B49" ref-type="bibr">49</xref> with permission from the American Urological Association.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T5" position="float"><label>Table 5</label><caption><p>Effect of 5Alpha-Reductase Inhibition Therapy on Efficiency of KTP Laser PVP</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"></th><th rowspan="1" colspan="1">Without 5α-Reductase</th><th rowspan="1" colspan="1">With 5α-Reductase</th><th rowspan="1" colspan="1"></th></tr><tr><th rowspan="1" colspan="1">IPSS</th><th rowspan="1" colspan="1">Inhibition (n)</th><th rowspan="1" colspan="1">Inhibition (n)</th><th rowspan="1" colspan="1"><italic>P</italic> Value</th></tr></thead><tbody valign="top"><tr><td rowspan="1" colspan="1">Baseline</td><td rowspan="1" colspan="1">26.9 ± 6.9 (117)</td><td rowspan="1" colspan="1">27.0 ± 7.8 (43)</td><td rowspan="1" colspan="1">.46</td></tr><tr><td rowspan="1" colspan="1">Follow-up Period</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1">(weeks)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">14.7 ± 8.0 (104)</td><td rowspan="1" colspan="1">14.8 ± 7.5 (40)</td><td rowspan="1" colspan="1">.46</td></tr><tr><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">10.7 ± 7.2 (97)</td><td rowspan="1" colspan="1">10.4 ± 6.1 (40)</td><td rowspan="1" colspan="1">.40</td></tr><tr><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">9.6 ± 7.3 (81)</td><td rowspan="1" colspan="1">8.4 ± 5.2 (32)</td><td rowspan="1" colspan="1">.21</td></tr><tr><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">8.5 ± 6.0 (46)</td><td rowspan="1" colspan="1">6.4 ± 4.5 (21)</td><td rowspan="1" colspan="1">.10</td></tr><tr><td rowspan="1" colspan="1">52</td><td rowspan="1" colspan="1">5.6 ± 4.4 (21)</td><td rowspan="1" colspan="1">7.0 ± 7.1 (8)</td><td rowspan="1" colspan="1">.36</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"></th><th rowspan="1" colspan="1">Without 5α-Reductase</th><th rowspan="1" colspan="1">With 5α-Reductase</th><th rowspan="1" colspan="1"></th></tr><tr><th rowspan="1" colspan="1">Qmax (mL/sec)</th><th rowspan="1" colspan="1">Inhibition (n)</th><th rowspan="1" colspan="1">Inhibition (n)</th><th rowspan="1" colspan="1"><italic>P</italic> Value</th></tr></thead><tbody valign="top"><tr><td rowspan="1" colspan="1">Baseline</td><td rowspan="1" colspan="1">10.7 ± 5.8 (117)</td><td rowspan="1" colspan="1">11.4 ± 6.1 (43)</td><td rowspan="1" colspan="1">.25</td></tr><tr><td rowspan="1" colspan="1">Follow-up Period</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1">(weeks)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">17.1 ± 8.2 (104)</td><td rowspan="1" colspan="1">18.0 ± 7.0 (40)</td><td rowspan="1" colspan="1">.29</td></tr><tr><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">20.5 ± 9.0 (97)</td><td rowspan="1" colspan="1">21.7 ± 8.7 (40)</td><td rowspan="1" colspan="1">.24</td></tr><tr><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">21.9 ± 9.3 (81)</td><td rowspan="1" colspan="1">23.1 ± 8.0 (32)</td><td rowspan="1" colspan="1">.28</td></tr><tr><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">20.6 ± 8.2 (46)</td><td rowspan="1" colspan="1">23.9 ± 76 (21)</td><td rowspan="1" colspan="1">.08</td></tr><tr><td rowspan="1" colspan="1">52</td><td rowspan="1" colspan="1">18.2 ± 6.3 (21)</td><td rowspan="1" colspan="1">16.9 ± 1.1 (8)</td><td rowspan="1" colspan="1">.39</td></tr></tbody></table><table-wrap-foot><fn><p>KTP, potassium-titanyl-phosphate; PVP, photoselective vaporization prostatectomy; Qmax, maximum flow rate. Reprinted from Araki et al<xref rid="B66" ref-type="bibr">66</xref> with permission from the American Urological Association.</p></fn></table-wrap-foot></table-wrap></floats-wrap></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Terre/explor/ThuliumV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000202 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000202 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Terre
|area= ThuliumV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.21. |  |